RIO DE JANEIRO, BRAZIL - British drugmaker AstraZeneca said on Saturday, February 6th, its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease conditions caused by the South African variant of COVID-19, based on early data from a trial.
The study from South Africa's University of the Witwatersrand and Oxford University showed the vaccine had significantly reduced efficacy against the South African variant, according to a Financial Times report published earlier in the day.
Among coronavirus variants currently most concerning for scientists and public health experts are the so-called British, South . . .